Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibin subunit beta E is a protein encoded by the INHBE gene, primarily expressed in the liver and belonging to the transforming growth factor-beta (TGF-beta) superfamily[2][7]. It forms part of activin E, a hepatokine that acts as a secreted cytokine, regulating diverse biological pathways including hormone secretion at the hypothalamic-pituitary axis and metabolic homeostasis[1][4][7]. INHBE variants have been linked to reduced abdominal fat distribution and lower risk of cardiometabolic disease, suggesting a therapeutic potential for obesity-related conditions[1]. INHBE is upregulated by interferon-beta1a in carcinoma cell lines, and alterations in its expression may affect processes such as insulin resistance and cell proliferation[5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibin subunit beta E (INHBE).